Jedd Wolchok receives Hearst Foundation Grant

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Jed Wolchok

Jedd Wolchok received a $1 million grant over a three-year period from The William Randolph Hearst Foundation to establish a new immuno-oncology research fellowship at Memorial Sloan Kettering Cancer Center, and support postdoctoral students who are conducting exceptional research in the field of immune-oncology and immunotherapy.

Wolchok is the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation, chief of the Immuno-Oncology Service, director of the Parker Institute for Cancer Immunotherapy, and associate director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.

The fellowship program will be a part of the Human Oncology and Pathogenesis Program’s Immuno-Oncology service, led by Wolchok.

Table of Contents

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login